Chris Shibutani
Stock Analyst at Goldman Sachs
(3.25)
# 2,988
Out of 4,873 analysts
99
Total ratings
51.92%
Success rate
1.35%
Average return
Main Sectors:
Stocks Rated by Chris Shibutani
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PCVX Vaxcyte | Maintains: Buy | $138 → $100 | $32.88 | +204.14% | 2 | Apr 1, 2025 | |
| ERAS Erasca | Maintains: Buy | $3.5 → $3 | $1.26 | +138.10% | 7 | Mar 21, 2025 | |
| MCRB Seres Therapeutics | Maintains: Sell | $20 → $15 | $9.51 | +57.73% | 4 | Mar 14, 2025 | |
| ALKS Alkermes | Maintains: Buy | $30 → $32 | $28.83 | +11.00% | 7 | Feb 14, 2025 | |
| BNTX BioNTech SE | Upgrades: Buy | $90 → $137 | $106.14 | +29.07% | 7 | Nov 8, 2024 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $30 → $33 | $9.29 | +255.22% | 3 | Nov 7, 2024 | |
| UTHR United Therapeutics | Maintains: Neutral | $243 → $302 | $284.09 | +6.30% | 4 | Nov 1, 2024 | |
| RPRX Royalty Pharma | Maintains: Buy | $50 → $51 | $35.27 | +44.60% | 3 | Aug 14, 2024 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $160 → $155 | $152.01 | +1.97% | 3 | Jul 19, 2024 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Neutral | $3 → $4 | $6.50 | -38.46% | 8 | Jul 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $20 | $9.98 | +100.40% | 5 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $650 → $723 | $795.12 | -9.07% | 6 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $29 → $26 | $20.49 | +26.89% | 1 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $134 → $153 | $126.71 | +20.75% | 2 | Jan 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $173 | $186.79 | -7.38% | 4 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $29.68 | - | 4 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $81 → $69 | $46.65 | +47.91% | 5 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $13 | $20.36 | -36.15% | 2 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $23 | $37.52 | -38.69% | 3 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $2.45 | +1,940.82% | 1 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $52 | $45.71 | +13.76% | 2 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $47 → $60 | $24.24 | +147.52% | 2 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $18 | $7.02 | +156.41% | 4 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $4.92 | +245.53% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.40 | - | 1 | Jul 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $3.69 | - | 1 | Feb 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $3.31 | - | 4 | Jan 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $29.64 | - | 3 | May 2, 2017 |
Vaxcyte
Apr 1, 2025
Maintains: Buy
Price Target: $138 → $100
Current: $32.88
Upside: +204.14%
Erasca
Mar 21, 2025
Maintains: Buy
Price Target: $3.5 → $3
Current: $1.26
Upside: +138.10%
Seres Therapeutics
Mar 14, 2025
Maintains: Sell
Price Target: $20 → $15
Current: $9.51
Upside: +57.73%
Alkermes
Feb 14, 2025
Maintains: Buy
Price Target: $30 → $32
Current: $28.83
Upside: +11.00%
BioNTech SE
Nov 8, 2024
Upgrades: Buy
Price Target: $90 → $137
Current: $106.14
Upside: +29.07%
Syndax Pharmaceuticals
Nov 7, 2024
Maintains: Buy
Price Target: $30 → $33
Current: $9.29
Upside: +255.22%
United Therapeutics
Nov 1, 2024
Maintains: Neutral
Price Target: $243 → $302
Current: $284.09
Upside: +6.30%
Royalty Pharma
Aug 14, 2024
Maintains: Buy
Price Target: $50 → $51
Current: $35.27
Upside: +44.60%
Johnson & Johnson
Jul 19, 2024
Maintains: Neutral
Price Target: $160 → $155
Current: $152.01
Upside: +1.97%
Amylyx Pharmaceuticals
Jul 12, 2024
Maintains: Neutral
Price Target: $3 → $4
Current: $6.50
Upside: -38.46%
May 6, 2024
Maintains: Neutral
Price Target: $18 → $20
Current: $9.98
Upside: +100.40%
Apr 11, 2024
Maintains: Neutral
Price Target: $650 → $723
Current: $795.12
Upside: -9.07%
Mar 1, 2024
Maintains: Neutral
Price Target: $29 → $26
Current: $20.49
Upside: +26.89%
Jan 25, 2024
Maintains: Buy
Price Target: $134 → $153
Current: $126.71
Upside: +20.75%
Dec 11, 2023
Upgrades: Buy
Price Target: $173
Current: $186.79
Upside: -7.38%
Nov 9, 2023
Upgrades: Outperform
Price Target: n/a
Current: $29.68
Upside: -
Oct 30, 2023
Maintains: Buy
Price Target: $81 → $69
Current: $46.65
Upside: +47.91%
Mar 3, 2023
Maintains: Neutral
Price Target: $15 → $13
Current: $20.36
Upside: -36.15%
Mar 1, 2023
Maintains: Neutral
Price Target: $20 → $23
Current: $37.52
Upside: -38.69%
Dec 19, 2022
Initiates: Buy
Price Target: $50
Current: $2.45
Upside: +1,940.82%
Dec 16, 2022
Maintains: Buy
Price Target: $40 → $52
Current: $45.71
Upside: +13.76%
Dec 13, 2022
Upgrades: Buy
Price Target: $47 → $60
Current: $24.24
Upside: +147.52%
Nov 8, 2022
Maintains: Neutral
Price Target: $13 → $18
Current: $7.02
Upside: +156.41%
Sep 7, 2021
Initiates: Buy
Price Target: $17
Current: $4.92
Upside: +245.53%
Jul 14, 2020
Initiates: Outperform
Price Target: n/a
Current: $1.40
Upside: -
Feb 10, 2020
Initiates: Outperform
Price Target: n/a
Current: $3.69
Upside: -
Jan 24, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $3.31
Upside: -
May 2, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $29.64
Upside: -